ArticleCancer discovery2018
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 2 syntheses or guidelines pooled it, 249 citations in OpenAlex.
- Dynamic Cytokine Relationships Across the Blood-Brain Barrier in Humans and Nonhuman Primates-Implications for Psychiatric Illness: A Systematic Review.Biological psychiatry · 2026Pooled it
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.Nature reviews. Clinical oncology · 2019Guideline
- PLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy.Journal for immunotherapy of cancer · 2026Article
- Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion.Brain, behavior, & immunity - health · 2026Article
- The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy.Cancer research · 2026Review
- Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.Oncogene · 2026Article
- Determinants of Chimeric Antigen Receptor (CAR) T Cell Success: In Vitro and In Vivo Preclinical Assessment.Cancers · 2026Review
- mRNA medicine for cardiovascular disease.Nature cardiovascular research · 2026Review
- Immunogenicity of Gene and Cell Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A motif-vocabulary model of CAR T-cell intracellular domains identifies determinants of immunophenotype differentiation.bioRxiv : the preprint server for biology · 2026Article
- Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.Nature communications · 2026Article
- The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy.Frontiers in immunology · 2026Review
- CAR-T Cell Therapy for Central Nervous System Tumors.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Spatio-temporal kinetics of patients' CAR-T cells in blood and serous cavity effusion: real-world clinical insights.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Article
- Article
- Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells.Molecular therapy. Methods & clinical development · 2025Article
- Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in rhesus macaques.Blood advances · 2025Article
- Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.International journal of molecular sciences · 2025Article
- CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors.Molecular therapy. Oncology · 2025Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 1 country.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell immunotherapy has revolutionized the treatment of refractory leukemias and lymphomas, but is associated with significant toxicities, namely cytokine release syndrome (CRS) and neurotoxicity. A major barrier to developing therapeutics to prevent CAR T cell-mediated neurotoxicity is the lack of clinically relevant models. Accordingly, we developed a rhesus macaque (RM) model of neurotoxicity via adoptive transfer of autologous CD20-specific CAR T cells. Following cyclophosphamide lymphodepletion, CD20 CAR T cells expand to 272 to 4,450 cells/μL after 7 to 8 days and elicit CRS and neurotoxicity. Toxicities are associated with elevated serum IL6, IL8, IL1RA, MIG, and I-TAC levels, and disproportionately high cerebrospinal fluid (CSF) IL6, IL2, GM-CSF, and VEGF levels. During neurotoxicity, both CD20 CAR and non-CAR T cells accumulate in the CSF and in the brain parenchyma. This RM model demonstrates that CAR T cell-mediated neurotoxicity is associated with proinflammatory CSF cytokines and a pan-T cell encephalitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.